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Reinfection of chronic chagasic mice after treatment with nifurtimox resulted in different outcomes
according to the number of parasites used for inoculation. Nifurtimox-treated chagasic animals injected with
2,500 trypomastigotes developed higher parasitemia and increased mortality compared with nontreated
chagasic mice. When reinfection was done with 25 trypomastigotes, treated and nontreated animals showed
similar parasitemias and mortalities, which were significantly higher in nonchagasic controls infected for the
first time. Immunological studies showed that treatment with nifurtimox led to a decrease in anti-Trypanosoma
cruzi antibodies engaged in parasite destruction, inducing either complement-dependent lysis or antibody-
dependent cytotoxicity, but no difference in anti-T. cruzi cell-mediated immunity was found between treated
and nontreated chagasic animals. It is concluded that treatment with nifurtimox leads to a loss of resistance to
reinfection with a large number of trypanosomes, which is maintained with challenge with a few parasites, and
that these two thresholds of premunition are probably associated with humoral and cell-mediated anti-T. cruzi
immune responses, respectively.
Human or animal infection with Trypanosoma cruzi is
lifelong. It is usually held that chronically infected hosts are
resistant to new infections (2).
The terms premunition and concomitant immunity have
been coined to define this situation. Apparently, resistance
depends on a permanent antigenic stimulation due to the
persistence of living parasites in the organism. Sterilization
induced by treatment with trypanocidal drugs leads to a loss
of premunition (3), and successful reinfection of treated
animals is considered to be an index of parasitological
sterilization.
In most assays performed for determination of premuni-
tion, reinfection is done with a large and usually lethal
number of parasites. To our knowledge, the result of rein-
fection with a low number of parasites in animals parasito-
logically sterilized by treatment with trypanocidal drugs has
not been explored. This information would be relevant for a
better understanding of the human situation, since most
patients treated during the acute or chronic stage of the
disease remain living in areas endemic for T. cruzi and are
therefore exposed to reinfection with a low number of
parasites.
We report here the evolution of chronic chagasic mice
treated with nifurtimox and reinfected with a high or low
number of parasites and the effect of a trypanocidal drug on
the humoral and cell-mediated anti-T. cruzi immune re-
sponse, in order to investigate the putative mechanisms
involved with the maintenance or loss of the premunition
state.
MATERIALS AND METHODS
Experimental design. Chronic Chagas' disease was in-
duced in mice as previously reported (10). Briefly, 3-month-
old female BALB/c mice were infected by the intraperitoneal
route with 25 trypomastigotes of the Tulahuen strain of T.
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cruzi. Parasitemia was determined weekly, and surviving
animals which showed circulating parasites during month 1
of the postinfection (p.i.) period were used for the experi-
ments. At 3 months p.i., mice were treated with nifurtimox
(100 mg/kg [body weight]) daily for 30 days by the intragas-
tric route (group 1). As controls, chagasic animals received
distilled water (group 2) and noninfected mice of matching
age and sex received nifurtimox daily (group 3) by the same
route.
Two months after the end of treatment, (i) from 15 animals
in each group blood was collected from the retro-orbital
plexus for subinoculation and for cell and serum separation
for immunological studies, (ii) 10 mice from each group were
injected in the hind footpad with T. cruzi antigens, and (iii) 20
mice from each group were infected with either 25 or 2,500
trypomastigotes. In these animals, mortality was determined
daily and parasitemia was determined weekly for 5 weeks.
Anti-T. cruzi antibodies. Conventional serology was per-
formed by standard immunofluorescence (5) and hemagglu-
tination (13) techniques. Complement-dependent lytic anti-
bodies were investigated by the method of Krettli and
Brener (8). Briefly, T. cruzi trypomastigotes were collected
at day 7 p.i. from the peripheral blood of lethally irradiated
(800 rads) mice. Parasites were incubated with fresh human
serum for 45 min at 37°C and washed thoroughly with RPMI
1640 medium with HEPES (N-2-hydroxyethylpiperazine-N'-
2-ethanesulfonic acid) buffer. Mouse test serum was pre-
heated (56°C for 30 min) and diluted 1/4 in RPMI 1640
medium-HEPES, and 106 trypomastigotes were incubated
with 50 RI of diluted test serum for 1 h at 37°C. After 1 h, 50
,ul of fresh or preheated (56°C for 30 min) human serum was
incorporated, and after incubation for 45 min at 37°C the
parasites were counted in a hemacytometer. Lysis was
calculated as follows: % lysis = number of parasites after
incubation with fresh human serum/number of parasites after
incubation with preheated human serum x 100. Lysis higher
than 30% was considered positive.
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TABLE 1. Anti-T. -ruzi humoral immune response
No. positive/total no. of mice ADCC (% of lysis + SD) with effector cells:
Chagasic mouse
group emaggutinaion' mmunoluorecence Complement- Polymorphonuclear Blonodula Spnnuleengroup Hemag l inat " Immunofluorescenceb dependent lysis' leukocytes leuk cytes cells
Nontreated 13/14 13/14 12/14 69 ± 58 ± 12e 57 ± 13.5f
Nifurtimox treated 9/11 10/13 0/13 17 ± 10.4d 17.6 ± 13' 13.6 ± 9.9'
a Titer higher than 1/40.
b Titer higher than 1/32.
Positive, Lysis higher than 30%.
d p < 0.0005 (Student's t test).
Pp < 0.05 (Student's t test).
f P < 0.025 (Student's t test).
Anti-T. cruzi cell-mediated immunity. Increase in the
weight of the popliteal lymph node and production of leu-
kocyte-inhibition-migrating factor were used for studying
anti-T. cruzi cell-mediated immunity. As the antigen, a
whole homogenate of T. cruzi epimastigotes grown in dipha-
sic medium and disrupted by compression-decompression
was used (16). To determine the increase in weight of the
popliteal lymph node, 0.04 ml of the whole homogenate
containing 100 p.g of protein was injected into the hind
footpad. The contralateral footpad received 0.04 ml of T.
cruzi culture medium. Three days later, the animals were
killed and the popliteal lymph nodes were dissected and
weighed, For investigation of leukocyte-inhibition-migrating
factor production, blood from the retro-orbital plexus was
collected in heparinized tubes and left to sediment in 6%
dextran for 1 h at 37°C. The leukocytes were washed three
times in RPMI 1640 medium with HEPES buffer, placed (2 x
105) in capillary tubes with one sealed end, and centrifuged.
The capillary tubes, sectioned above the leukocyte layer,
were placed in Falcon petri dishes with RPMI 1640-HEPES
medium containing 10% fetal bovine serum and T. cruzi
homogenate (100 ,g of whole protein) and incubated for 24 h
at 37°C in a 5% CO2 atmosphere. As a control, the same
procedure was used with culture medium alone. The surface
area of migrating cells was estimated with a calibrated
eyepiece. Inhibition of migration was determined with the
following equation: % inhibition = mean area with antigen/
mean area without antigen x 100. Determinations were
triplicated for each animal.
Subinoculation. A 0.2-ml sample of blood was injected
intraperitoneally into suckling Swiss albino mice. Mortality
was recorded daily, and parasites were sought weekly in
blood by direct microscopic examination.
ADCC. Antibody-dependent cytotoxicity (ADCC) was
investigated by the method of Kierszenbaum (7). T. cruzi
trypomastigotes were collected from irradiated mice. Mono-
nuclear and polymorphonuclear leukocytes from blood and
mononuclear spleen cells were collected in a Ficoll-Hypaque
gradient. Trypomastigotes and cells were incubated 2/1 with
the test sera or with noninfected mouse serum diluted 1/10 in
RPMI 1640-HEPES medium for 5 h at 37°C. The number of
surviving parasites was determined in a hemacytometer.
ADCC was calculated as follows: ADCC = 100 - number of
parasites incubated with test serum/number of parasites
incubated with normal serum x 100.
Statistics. Statistical analyses were performed by using the
x2 test and Student's t test.
RESULTS
Effect of nifurtimox treatment. In the control nontreated
mice chronically infected with the Tulahuen strain of T.
cruzi, circulating parasites could be recovered from all
animals by inoculation of blood into suckling mice, although
no parasites were observed by direct microscopic examina-
tion. Two months after the 30-day treatment of chagasic
mice with nifurtimox, no parasites could be recovered by
subinoculation into suckling mice. No mortality was ob-
served in either the nontreated or the treated group.
Anti-T. cruzi antibodies demonstrable by conventional
immunofluorescence and hemagglutination techniques were
present in the sera of all treated and nontreated chagasic
mice, but those inducing complement-dependent lysis of the
parasite or ADCC activity could not be demonstrated after
treatment, although they were present in the sera of most of
the nontreated chagasic mice (Table 1). The investigation of
ahti-T. cruzi cell-mediated immunity did not show differ-
ences between the nontreated and nifurtimox-treated in-
fected mice (Table 2).
Evolution of mice reinfected with 2,500 trypomastigotes.
Cumulative mortality was high in the chagasic animals
treated with nifurtimox, and at 5 weeks p.i. all were dead.
Nontreated reinfected chagasic mice and those infected for
the first time with 2,500 parasites showed similar mortalities,
and at the end of the experiment half of the mice were still
alive (Fig. 1). In the group of nontreated chagasic mice,
about 50% of the animals showed patent microscopic para-
sitemia at 7 days p.i., but with the weekly samples obtained
thereafter the number of animals with positive parasitemia
decreased, and at 5 weeks postreinfection no parasites could
be seen in the surviving animals. In the remaining two
groups, all the animals showed circulating parasites during
the entire experiment (Fig. 2).
The numbers of circulating parasites were different in the
three groups. As can be seen in Fig. 3, in the nifurtimox-
treated chagasic mice the number of parasites increased
steadily until week 4 postreinfection. Meanwhile, in the
nontreated and reinfected chagasic mice the number of
parasites was significantly lower during weeks 1 and 2
postreinfection, when animals with circulating parasites
were still present. In mice infected for the first time, the
TABLE 2. Anti-T. cruzi cell-mediated immune responsea
Mouse group LIFb (%) Popliteal lymphnode test' (mg)
Noninfected 4.16 ± 2.48d +0.6 ± 0.14d
Nontreated chagasic 92.5 ± 5.2 +5.43 ± 1.99
Nifurtimox-treated chagasic 84.6 ± 3.91 +8.56 + 4.3
" Data are the means for 10 mice + standard error of the mean.
b LIF, Leukocyte-inhibition-migrating factor.
' Difference in weight between test and contralateral lymph nodes.
d P < 0.005 compared with the remaining two groups (Student's t test).
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FIG. 1. Percent mortality in nifurtimox-treated chagasic mice
(=) after reinfection with 25 or 2,500 trypomastigotes. E i,
Nonchagasic mice; _, nontreated chagasic mice; **, P < 0.01 (X2
test); *, P < 0.05 (x2 test).
number of parasites was always higher than in the chagasic
animals, although a marked weekly variation was observed.
Evolution of chagasic mice reinfected with 25 trypomasti-
gotes. As can be seen in Fig. 2, about 75% of the animals
infected the first time presented patent parasitemia during
the experiment. In the chagasic animals, either treated with
nifurtimox or nontreated, the number of animals with posi-
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FIG. 3. Number of circulating parasites per milliliter in nifurti-
mox-treated chagasic mice reinfected with 2,500 trypomastigotes.
0, Nontreated chagasic mice; *, mice infected for the first time; #,
nifurtimox-treated chagasic mice.
tive parasitemia was significantly lower than in the previous
group, as was the number of circulating parasites, which was
higher in the mice infected for the first time (Fig. 4). In this
group, mortality attained 60% after week 3 p.i. Meanwhile,
in the chagasic mice, either nifurtimox treated or untreated,
mortality was below 10% at the end of the 5-week observa-
tion time (Fig. 1).
DISCUSSION
Our observations show that the reinfection of nifurtimox-
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FIG. 2. Percentage of mice presenting circulating parasites by
direct microscopic examination. Each bar represents the percentage
of 20 mice. rizi, Nonchagasic mice; _, nontreated chagasic mice;
E, nifurtimox-treated chagasic mice.
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FIG. 4. Number of circulating parasites per milliliter in nifurti-
mox-treated chagasic mice reinfected with 25 trypomastigotes. 0,
Nontreated chagasic mice; *, mice infected for the first time; #,
nifurtimox-treated chagasic mice.
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from that of nontreated animals according to the number of
parasites used for reinoculation. Compared with the non-
treated chronically infected animals, which were relatively
resistant to reinfection with a high number of parasites,
treated animals showed higher parasitemia and mortality.
This indicates that they had lost their premunition state,
which is associated with parasitological sterilization, accord-
ing to accepted criteria (3). The fact that premunition was
not completely protective, since reinfected chagasic mice
presented a transient elevation of parasitemia and 50%
mortality, is in agreement with previous observations from
our laboratory (4).
It was surprising that the progress of the disease in
nifurtimox-treated chagasic animals reinfected with 2,500
trypomastigotes was more severe than that observed in
control mice infected for the first time with the same number
of parasites. The possibility that treatment with nifurtimox
induced an immune depression appears unlikely, since the
latter animals also received the drug. Moreover, although
nifurtimox can induce an immune depression, especially on
cell-mediated immunity (11), the 2 months elapsed between
the end of treatment and reinfection and the fact that the
anti-T. cruzi cell-mediated immune response was similar in
both the nifurtimox-treated and the nontreated chagasic
mice support the opinion that the drug is not directly
responsible for the exacerbated course of reinfection.
However, other explanations, such as the possibility that
reinfection after nifurtimox treatment induces a secondary
immune response with prevalence of antibodies not directly
engaged in parasite destruction or even with a protective
ability, remain to be explored.
When mice were reinfected with a low number of para-
sites, no difference was found between nifurtimox-treated
and nontreated chagasic mice. The incidences of parasitemia
and mortality were similar in both groups and were signifi-
cantly lower than in the untested control mice, indicating a
persistence of premunition, although the number of circulat-
ing parasites was higher in the treated than in the nontreated
infected animals.
This different behavior in the evolution of reinfection with
a few parasites in nifurtimox-treated chagasic mice com-
pared with those challenged with a higher number of para-
sites can be tentatively correlated with the different effects of
treatment on the humoral and cell-mediated anti-T. cruzi
immune response. Antibodies inducing complement-depen-
dent lysis and ADCC of the parasite could not be demon-
strated 2 months after treatment, but a strong cell-mediated
immune response was still present at that time. These
observations suggest that the latter could be able to protect
against a small number of parasites but would be over-
whelmed with larger inocula, when anti-T. cruzi antibodies
should be necessary to interfere successfully with the infec-
tion. Although cell-mediated anti-T. cruzi immunity has been
repeatedly demonstrated in chronically infected humans and
animals, its role in antiparasitic defense is not clear. Current
opinion holds that antibodies inducing either complement-
mediating lysis (9) or ADCC are the main protective mech-
anisms and that cellular immunity plays a minor role (18, 19).
The results of our study are relevant for the human situation.
Trypanocidal drugs are indicated for treatment of Chagas'
disease during acute infection, because in this situation
parasitological sterilization can frequently be obtained (1). In
the chronic stage, although treatment is less efficient, occa-
sional "cures" have been reported (6). Knowledge about
sensitivity to reinfection in treated patients living in endemic
areas, where they are constantly exposed to new infections,
should be relevant, either to determine resistance of treated
humans or to consider the possibility of altering the parasite
cycle by treatment of the intermediate hosts, such as dogs.
In addition, the fact that our results show that apparently
there are two thresholds of premunition to reinfection with
T. cruzi, one for a low number of parasites, probably
dependent on cellular immune mechanisms, and another for
a high number, related to humoral immunity, should be
useful for vaccine trials. Most studies on resistance after
immunization with either attenuated strains (12), T. cruzi
fragments (14), or surface glycoproteins (15, 17) have fo-
cused on the humoral response, and test challenges have
been made with a large number of parasites. In our opinion,
these studies should also include evaluation of anti-T. cruzi
cell-mediated immune responses and challenge with a small
number of parasites, simulating some of the conditions of
human infection.
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